Phibro Animal Health Bolsa (NASDAQ: PAHC)

Phibro Animal Health (NASDAQ:PAHC) Bolsa

Phibro Animal Health

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health Corp

Here are two stocks with buy rank and strong value characteristics for investors to consider today, February 14th:
Adtalem Global Education Inc. ATGE: This workforce solutions company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.6% over the last 60 days.
<div class="chart_embed">
<h3>Adtalem Global Education Inc. Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/ATGE/price-consensus-chart?icid=chart-ATGE-price-consensus-chart"><img alt="Adtalem Global Education Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/56/1739522157.png" style="height:264px; width:573px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/ATGE/price-consensus-chart?icid=chart-ATGE-price-consensus-chart">Adtalem Global Education Inc. price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/ATGE?icid=chart-ATGE-price-consensus-chart">Adtalem Global Education Inc. Quote</a>
</div>
Adtalem has a price-to-earnings ratio (P/E) of 17.38, compared with 23.50 for the industry. The company possesses a <a href="https://www.zacks.com/style-scores-education/">Value Score</a>&nbsp; of B.
<div class="chart_embed">
<h3>Adtalem Global Education Inc. PE Ratio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ttm#NYSE">TTM</a>)</h3>
<a href="https://www.zacks.com/stock/chart/ATGE/fundamental/pe-ratio-ttm?icid=chart-ATGE-fundamental/pe-ratio-ttm">TTM</a>)&quot; height=&quot;250&quot; src=&quot;https://staticx-tuner.zacks.com/images/charts/cd/1739522299.png&quot; title=&quot;&quot; width=&quot;533&quot; /&gt;
<a href="https://www.zacks.com/stock/chart/ATGE/fundamental/pe-ratio-ttm?icid=chart-ATGE-fundamental/pe-ratio-ttm">Adtalem Global Education Inc. pe-ratio-ttm</a> | <a href="https://www.zacks.com/stock/quote/ATGE?icid=chart-ATGE-fundamental/pe-ratio-ttm">Adtalem Global Education Inc. Quote</a>
</div>
Phibro Animal Health Corporation PAHC: This animal health and mineral nutrition company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.6% over the last 60 days.
<div class="chart_embed">
<h3>Phibro Animal Health Corporation Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/PAHC/price-consensus-chart?icid=chart-PAHC-price-consensus-chart"><img alt="Phibro Animal Health Corporation Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/ce/1739522170.png" style="height:264px; width:568px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/PAHC/price-consensus-chart?icid=chart-PAHC-price-consensus-chart">Phibro Animal Health Corporation price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/PAHC?icid=chart-PAHC-price-consensus-chart">Phibro Animal Health Corporation Quote</a>
</div>
Phibro has a price-to-earnings ratio (P/E) of 14.41, compared with 21.88 for the S&amp;P 500. The company possesses a Value Score of A.
<div class="chart_embed">
<h3>Phibro Animal Health Corporation PE Ratio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ttm#NYSE">TTM</a>)</h3>
<a href="https://www.zacks.com/stock/chart/PAHC/fundamental/pe-ratio-ttm?icid=chart-PAHC-fundamental/pe-ratio-ttm">TTM</a>)&quot; height=&quot;250&quot; src=&quot;https://staticx-tuner.zacks.com/images/charts/25/1739522333.png&quot; title=&quot;&quot; width=&quot;533&quot; /&gt;
<a href="https://www.zacks.com/stock/chart/PAHC/fundamental/pe-ratio-ttm?icid=chart-PAHC-fundamental/pe-ratio-ttm">Phibro Animal Health Corporation pe-ratio-ttm</a> | <a href="https://www.zacks.com/stock/quote/PAHC?icid=chart-PAHC-fundamental/pe-ratio-ttm">Phibro Animal Health Corporation Quote</a>
</div>
&nbsp;
See <a href="https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&amp;ICID=zpi%20_1link">the full list of top ranked stocks here.</a>
&nbsp;
Learn more about the <a href="https://www.zacks.com/education/stock-scorecard/value-trading">Value score and how it is calculated here.</a>
&nbsp;
<h2>7 Best Stocks for the Next 30 Days</h2>
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers &quot;Most Likely for Early Price Pops.&quot;
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand picked 7 your immediate attention.&nbsp;
<a href="https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1473&amp;adid=SYND_BENZ_ZU_7BESTREPORTA_ZACKS1RANKADDITIONS_268_02142025_2415912&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2415912" style="font-weight:bold">See them now &gt;&gt;</a>
&nbsp;
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href="https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&amp;ADID=SYND_BENZ_7BEST_ZACKS1RANKADDITIONS_268_2415912&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2415912" target="_blank">Click to get this free report</a>

&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=PAHC&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_268_2415912_PAHC&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2415912">Phibro Animal Health Corporation (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/pahc#NASDAQ">PAHC</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=ATGE&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_268_2415912_ATGE&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2415912">Adtalem Global Education Inc. (ATGE): Free Stock Analysis Report</a>
<a href="https://www.zacks.com/commentary/2415912/best-value-stocks-to-buy-for-february-14th?cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2415912">To read this article on Zacks.com click here.</a>
<a href="https://www.zacks.com/">Zacks Investment Research</a>

Equities

Small Cap

Markets

PAHC

Best Value Stocks To Buy For February 14th

WIIM

Phibro Animal Health shares are trading higher after Barclays raised its price target on the stock from $20 to $22.

News

Rumors

Analyst Ratings

Trading Ideas

Watching Phibro Animal Health; Hearing Popular Retail Trading Newsletter Picks Stock

Barclays analyst Balaji Prasad maintains Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) with a Underweight and raises the price target from $20 to $22.

Price Target

Barclays Maintains Underweight on Phibro Animal Health, Raises Price Target to $22

Phibro Animal Health shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance.

Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) raises FY2025 Adj EPS guidance from $1.34-1.48 to $1.87-2.01 vs $1.64 analyst estimate. Raises FY2025 sales outlook from $1.05 billion-1.10 billion to $1.25 billion-1.30 billion vs $1.27 billion estimate.

Guidance

Phibro Animal Health Raises FY2025 Adj EPS Guidance from $1.34-1.48 to $1.87-2.01 vs $1.64 Est; Raises FY2025 Sales Guidance from $1.05B-1.10B to $1.25B-1.30B vs $1.27B Est

Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.42 by 28.57 percent. This is a 63.64 percent increase over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $309.30 million which beat the analyst consensus estimate of $303.84 million by 1.80 percent. This is a 23.77 percent increase over sales of $249.90 million the same period last year.

Earnings

Earnings Beats

Phibro Animal Health Q2 Adj $0.54 Beats $0.42 Estimate, Sales $309.30M Beat $303.84M Estimate

Phibro Sees FY25 Revenue $1.257B-$1.30B Vs $1.27B Estimate

Phibro Animal Health Q2 2025 Adj EPS $0.54 Beats $0.42 Estimate, Sales $309.30M Beat $303.84M Estimate

ALGN

AMSC

AOSL

APPS

ARAY

ARCC

ARES

ASGN

ASYS

AZTA

BARK

BLBD

BSBR

CENT

CENTA

CMRE

CNMD

CNXN

COHR

CPAY

CPRI

CRTO

CSGS

CTSH

CTVA

DGII

DLHC

ENSG

EQNR

EZPW

FORM

GEOS

HOLX

ITUB

KMPR

LFVN

LSAK

LUCK

LVWR

MSTR

MTRX

MUSA

NOTV

NTGR

NVST

NWSA

ODFL

ORLY

PFGC

Earnings Scheduled For February 5, 2025

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Tuesday.
Shares of Limoneira Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) fell sharply in today's pre-market trading after reporting <a href="https://www.benzinga.com/quote/LMNR/news">fourth-quarter results.</a>
Limoneira posted an adjusted net loss of $1.6 million, or 9 cents per share, versus a year-ago loss of $2.6 million, or 15 cents per share. Its total net revenue rose to $43.9 million from $41.4 million in the year-ago quarter.
Limoneira shares fell 2.6% to $26.12 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Tutor Perini Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPC#NYSE">TPC</a>) dipped 12.1% to $22.01 in pre-market trading.</li>
<li>Astria Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) fell 11.8% to $8.40 in pre-market trading.</li>
<li>Jiayin Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) shares fell 7.5% to $5.95 in pre-market trading. Jiayin Group, last week, announced the purchase of commercial property located in Shanghai, China for total cash consideration of RMB1.35 billion.</li>
<li>AngioDynamics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) dipped 7.3% to $8.21 in pre-market trading. AngioDynamics will report financial results for the second quarter of fiscal year before the opening bell on Wednesday, Jan. 8, 2025.</li>
<li>Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) fell 5.2% to $20.51 in pre-market trading.</li>
<li>ADS-TEC Energy PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSE#NASDAQ">ADSE</a>) shares fell 3% to $13.70 in pre-market trading.</li>
<li>Vinci Partners Investments Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINP#NASDAQ">VINP</a>) fell 2.9% to $9.57 in pre-market trading.</li>
<li>Couchbase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) declined 2.4% to $14.91 in pre-market trading.</li>
<li>Turtle Beach Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEAR#NASDAQ">HEAR</a>) declined 2.3% to $15.60 in pre-market trading.</li>
<li>Valhi, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) fell 2% to $21.30 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42648003/how-to-earn-500-a-month-from-qualcomm-stock-2">How To Earn $500 A Month From Qualcomm Stock</a></li>
</ul>

Pre-Market Outlook

Movers

ADSE

ANGO

ATXS

BASE

HEAR

JFIN

LMNR

VINP

Limoneira And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Morgan Stanley analyst Erin Wright maintains Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) with a Equal-Weight and raises the price target from $20 to $25.

Morgan Stanley Maintains Equal-Weight on Phibro Animal Health, Raises Price Target to $25

Barclays analyst Balaji Prasad maintains Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) with a Underweight and raises the price target from $13 to $20.

Barclays Maintains Underweight on Phibro Animal Health, Raises Price Target to $20

CORRECTION: Phibro Animal Health Q1 2025 Adj. EPS $0.35 Beats $0.25 Estimate, Sales $260.400M Beat $244.400M Estimate

Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) raises FY2025 Adj EPS guidance from $1.22-1.37 to $1.34-1.48 vs $1.55 analyst estimate. Raises FY2025 sales outlook from $1.04 billion-1.09 billion to $1.05 billion-1.10 billion vs $1.21 billion estimate.

Phibro Animal Health Raises FY2025 Adj EPS Guidance from $1.22-1.37 to $1.34-1.48 vs $1.55 Est; Raises FY2025 Sales Guidance from $1.04B-1.09B to $1.05B-1.10B vs $1.21B Est

Phibro Sees FY25 Net Sales $1.05B-$1.1B Vs $1.21B Estimate

Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Phibro Animal Health to report an earnings per share (EPS) of $0.25.
Phibro Animal Health bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.08, leading to a 3.17% increase in the share price on the subsequent day.
Here's a look at Phibro Animal Health's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.33</td>
<td>0.29</td>
<td>0.28</td>
<td>0.23</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.41</td>
<td>0.31</td>
<td>0.33</td>
<td>0.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>3.0%</td>
<td>7.000000000000001%</td>
<td>-19.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730836895_0.png" alt="eps graph" />
<h3>Market Performance of Phibro Animal Health's Stock</h3>
Shares of Phibro Animal Health were trading at $22.37 as of November 04. Over the last 52-week period, shares are up 90.95%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Observations about Phibro Animal Health</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Phibro Animal Health.
Analysts have provided Phibro Animal Health with 2 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $18.5, suggesting a potential 17.3% downside.
<h3>Comparing Ratings with Competitors</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Liquidia, Evolus and EyePoint Pharmaceuticals, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>The prevailing sentiment among analysts is an Buy trajectory for Liquidia, with an average 1-year price target of $26.08, implying a potential 16.58% upside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for Evolus, with an average 1-year price target of $24.0, implying a potential 7.29% upside.</li>
<li>Analysts currently favor an Buy trajectory for EyePoint Pharmaceuticals, with an average 1-year price target of $24.0, suggesting a potential 7.29% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Liquidia, Evolus and EyePoint Pharmaceuticals, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phibro Animal Health</td>
<td>Neutral</td>
<td>7.10%</td>
<td>$87.15M</td>
<td>0.29%</td>
</tr>
<tr>
<td>Liquidia</td>
<td>Buy</td>
<td>-23.55%</td>
<td>$2.17M</td>
<td>-37.51%</td>
</tr>
<tr>
<td>Evolus</td>
<td>Buy</td>
<td>35.59%</td>
<td>$47.83M</td>
<td>-60.12%</td>
</tr>
<tr>
<td>EyePoint Pharmaceuticals</td>
<td>Buy</td>
<td>4.09%</td>
<td>$8.08M</td>
<td>-12.89%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Phibro Animal Health ranks at the top for Revenue Growth among its peers. It is at the bottom for Gross Profit and Return on Equity.
<h3>Unveiling the Story Behind Phibro Animal Health</h3>
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
<h3>Understanding the Numbers: Phibro Animal Health's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Phibro Animal Health showcased positive performance, achieving a revenue growth rate of 7.1% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Phibro Animal Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 0.28%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.29%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Phibro Animal Health's ROA excels beyond industry benchmarks, reaching 0.08%. This signifies efficient management of assets and strong financial health.
Debt Management: Phibro Animal Health's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.05, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<a href="https://www.benzinga.com/quote/PAHC/earnings">To track all earnings releases for Phibro Animal Health visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: Phibro Animal Health's Earnings Preview

U.S. stock futures were higher this morning, with the Dow futures gaining over 50 points on Friday.
Shares of Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) fell sharply in today's pre-market trading after the company lowered its annual production guidance due to supply shortage of shared component on the <a href="https://www.benzinga.com/markets/equities/24/10/41182921/rivians-production-forecast-hits-bump-supply-shortage-sends-shares-tumbling">R1 and RCV platforms</a>.
The company produced 13,157 vehicles at its manufacturing facility in Normal, Illinois, and delivered 10,018 cars during the same period. Rivian is experiencing a supply shortage that began in the third quarter of this year and has intensified in recent weeks.
Rivian Automotive shares dipped 6.8% to $10.05 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares declined 11.3% to $6.20 in pre-market trading.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) shares dipped 7% to $20.17 in pre-market trading after falling around 7% on Thursday.</li>
<li>Hyliion Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HYLN#NYSE">HYLN</a>) shares fell 5.7% to $2.3290 in pre-market trading. Hyliion recently announced its KARNO linear generator now qualifies under California&#8217;s renewables portfolio standard.</li>
<li>Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) shares fell 5.4% to $20.00 in pre-market trading,</li>
<li>AMTD Digital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HKD#NYSE">HKD</a>) shares fell 5.2% to $4.95 in pre-market trading after jumping over 33% on Thursday.</li>
<li>EVgo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) shares declined 4.4% to $6.04 in pre-market trading. EVgo shares jumped more than 60% on Thursday after the company announced it received a $1.05 billion conditional commitment for a Department of Energy (DOE) loan guarantee to accelerate the buildout of public fast charging across the US.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41180069/dow-tumbles-nearly-200-points-amid-growing-middle-east-concerns-investor-optimism-declines-fear-ind">Dow Tumbles Nearly 200 Points Amid Growing Middle East Concerns: Investor Optimism Declines, Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

EVGO

HYLN

RIVN

SAGE

Rivian Automotive Cuts Production Outlook, Joins EVgo And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Bruker Corporation&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brkr#NASDAQ">BRKR</a>) growth is backed by strong sales within its X-Ray and Nano Analytics businesses. Within the PCI division, expanding customer demand for pre-clinical MRI systems is highly encouraging. Meanwhile, the impact of macroeconomic pressure and currency fluctuation is likely to hurt the company&#39;s operational results.
In the past year, this Zacks Rank #3 (Hold) company&#39;s shares have gained 10.4% compared with the industry&#39;s 27.5% growth and the S&amp;P 500 composite&#39;s 34.9% gain.
This renowned medical device company has a market capitalization of $11.77 billion. It has a 2025 earnings growth rate of 17.6%, which is much higher than the industry&#39;s 13.8% growth rate. BRKR&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.1%.
Let&#39;s delve deeper.
<h2>Bruker&#39;s Key Upsides</h2>
Bright Prospects Within Nano Business Segment:&nbsp;The segment caters to a large set of customers, such as academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies and other businesses that are involved in materials research and life science research analysis. The business is seeing robust revenue growth across its end markets, including academic, government, industrial and semiconductor metrology.&nbsp;
During the first half of 2024, the company&#39;s advanced X-Ray and Nano Analytics businesses delivered strong sales, backed by Nano&#39;s robust revenue growth. Nano&#39;s strong growth is driven by the rising demand in academic and government markets. The Nanostring acquisition is expected to be both strategically and financially beneficial, promising a high return on investment for Bruker.
The Potential of Preclinical Imaging (PCI) Market: Per Grand View Research, the global PCI market was valued at $4.30 billion in 2023 and is likely to witness a CAGR of 4.6% up to 2030. Therefore, this translates into a golden opportunity for Bruker to expand its foothold in the PCI market and earn higher profits from this division.
Bruker offers advanced PCI solutions for a broad spectrum of application fields. Moreover, this division is experiencing increasing customer demand for higher-strength pre-clinical magnetic resonance imaging systems. Earlier this year, Bruker filled a critical gap in its PCI portfolio with the acquisition of Spectral Instruments Imaging LLC, a leader in preclinical in-vivo optical imaging systems.
<h2>Bruker&#39;s Key Downsides</h2>
Unfavorable Currency Movement: Bruker generates a substantial portion of its revenues in the international markets, primarily in Germany and other countries in the European Union, Switzerland and Japan.&nbsp; As a result, currency fluctuations continue to result in foreign currency transaction losses for the company. In addition, currency fluctuations are likely to cause the price of Bruker&#39;s products to be less competitive than its principal competitors&#39; offerings.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/6e/80173.jpg?v=35874249" />
Image Source: Zacks Investment Research
Macroeconomic Factors:&nbsp;Present global economic challenges and uncertainties have made it harder for Bruker to manage operations and predict financial outcomes. Geopolitical conditions are impacting its operational results. In addition, supply-chain risks also persist. All these issues are leading to higher costs and expenditures for the company, impacting its profitability.
In the second quarter, Bruker&#39;s cost of revenues increased 21.6% from the same period in 2023. SG&amp;A expenses surged 24.4%.
<h2>BRKR&#39;s Estimate Trend</h2>
The Zacks Consensus Estimate for Bruker&#39;s 2024 earnings per share remained unchanged at $2.61 for the past 30 days.
The consensus estimate for the company&#39;s 2024 revenues is pegged at $3.41 billion, indicating a 14.9% rise from the year-ago &nbsp;number.
<h2>Key Picks</h2>
Some better-ranked stocks in the broader medical space are&nbsp;TransMedix Group&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>),&nbsp;AxoGen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>) and Phibro Animal Health (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pahc#NASDAQ">PAHC</a>).
TransMedix Group&#39;s earnings are expected to surge 255.8% in 2024. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 287.5%. Shares of the company have risen 173.5% in the past year compared with the industry&#39;s 22.4% growth. TMDX sports a Zacks Rank #1 (Strong Buy) at present.
AxoGen, carrying a Zacks Rank #2 (Buy) at present, has an earning yield of 94.1% compared with the industry&#39;s 12.3%. Shares of the company have risen 194.6% compared with the industry&#39;s 22.3% growth over the past year.&nbsp;AXGN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.46%.
Phibro, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 21% for fiscal 2025 compared with the industry&#39;s 12.6%. In the past year, shares of PAHC have risen 72.7% compared with the industry&#39;s 25.2% growth. PAHC delivered a trailing four-quarter average earnings surprise of 4.10%.
<a href="https://www.zacks.com/stock/news/2345297/here-s-why-you-should-retain-brkr-stock-in-your-portfolio-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2345297">To read this article on Zacks.com click here.</a>

Macro Economic Events

Mid Cap

Offerings

Economics

AXGN

BRKR

TMDX

Here's Why You Should Retain BRKR Stock in Your Portfolio Now

JP Morgan analyst Ekaterina Knyazkova initiates coverage on Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) with a Neutral rating and announces Price Target of $22.

Initiation

JP Morgan Initiates Coverage On Phibro Animal Health with Neutral Rating, Announces Price Target of $22

Press Releases

Phibro Animal Health Corporation Completes Acquisition of Zoetis' Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products

Phibro Animal Health Corporation Declares Quarterly Dividend

Phibro Animal Health Corporation Reports First Quarter Results, Updates Financial Guidance

Phibro Animal Health Corporation to Host Webcast and Conference Call on Second Quarter Results

Phibro Animal Health Corporation Announces the Appointment of Joyce J. Lee to Its Board of Directors

Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance

Phibro Animal Health Corporation to Participate at Bank of America 2025 Virtual Animal Health Summit

Phibro Animal Health Corporation to Participate at Barclays Annual Global Healthcare Conference

Phibro Animal Health Corporation to Host Webcast and Conference Call on Third Quarter Results

Comments

Phibro Animal Health

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL